Youth Depression Alleviation with Anti-inflammatory Agents (YoDA-A): a randomised clinical trial of rosuvastatin and aspirin
Michael Berk, Mohammadreza Mohebbi, Olivia M Dean, Sue M Cotton, Andrew M Chanen, Seetal Dodd, Aswin Ratheesh, G Paul Amminger, Mark Phelan, Amber Weller, Andrew Mackinnon, Francesco Giorlando, Shelley Baird, Lisa Incerti, Rachel E Brodie, Natalie O Ferguson, Simon Rice, Miriam R Schafer, Edward Mullen, Sarah Hetrick Show all
BMC Medicine | BMC | Published : 2020
BACKGROUND: Inflammation contributes to the pathophysiology of major depressive disorder (MDD), and anti-inflammatory strategies might therefore have therapeutic potential. This trial aimed to determine whether adjunctive aspirin or rosuvastatin, compared with placebo, reduced depressive symptoms in young people (15-25 years). METHODS: YoDA-A, Youth Depression Alleviation with Anti-inflammatory Agents, was a 12-week triple-blind, randomised, controlled trial. Participants were young people (aged 15-25 years) with moderate to severe MDD (MADRS mean at baseline 32.5 ± 6.0; N = 130; age 20.2 ± 2.6; 60% female), recruited between June 2013 and June 2017 across six sites in Victoria, Australia. I..View full abstract
Awarded by National Health and Medical Research Council of Australia
The study was funded by the National Health and Medical Research Council of Australia (APP1027315) and sponsored by Orygen, the National Centre of Excellence in Youth Mental Health, without limitations on publication.